在3期OlympiA试验中，BRCA1或BRCA2突变的高危早期乳腺癌患者中，急性肾损伤与奥拉帕利的使用之间是否存在关联？ - Suppr | 超能文献

Is there any association between acute kidney injury and olaparib use in patients with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.

作者信息

Altundag Kadri

机构信息

MKA Breast Cancer Clinic, Tepe Prime, Cankaya, 06800, Ankara, Turkey.

出版信息

Breast Cancer. 2023 Nov;30(6):1107. doi: 10.1007/s12282-023-01469-y. Epub 2023 May 11.

DOI:10.1007/s12282-023-01469-y

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Is there any association between acute kidney injury and olaparib use in patients with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.在3期OlympiA试验中，BRCA1或BRCA2突变的高危早期乳腺癌患者中，急性肾损伤与奥拉帕利的使用之间是否存在关联？

Breast Cancer. 2023 Nov;30(6):1107. doi: 10.1007/s12282-023-01469-y. Epub 2023 May 11.

2

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.一项针对BRCA1或BRCA2突变的HER2阴性晚期乳腺癌一线治疗的I期试验，随后进行两个周期卡铂-奥拉帕利联合治疗，然后奥拉帕利单药治疗与卡培他滨对比的随机II期试验（REVIVAL）：一项随机对照试验的研究方案。

Trials. 2016 Jun 21;17(1):293. doi: 10.1186/s13063-016-1423-0.

3

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.奥拉帕利联合度伐利尤单抗治疗种系 BRCA 突变转移性乳腺癌患者（MEDIOLA）：一项开放标签、多中心、1/2 期、篮子研究。

Lancet Oncol. 2020 Sep;21(9):1155-1164. doi: 10.1016/S1470-2045(20)30324-7. Epub 2020 Aug 6.

4

Some subgroups might get less benefit from adjuvant olaparib trial in high-risk, HER2-negative and germline BRCA2 BRCA1- or BRCA2-mutated early breast cancer patients.在高危、HER2阴性且胚系BRCA2、BRCA1或BRCA2突变的早期乳腺癌患者中，一些亚组可能从辅助奥拉帕利试验中获益较少。

J BUON. 2021 Sep-Oct;26(5):2202.

5

Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.OlympiA 试验中来自日本的 BRCA1 或 BRCA2 突变的高风险早期乳腺癌患者亚组中辅助奥拉帕利的应用。

Breast Cancer. 2023 Jul;30(4):596-605. doi: 10.1007/s12282-023-01451-8. Epub 2023 Apr 1.

6

Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.奥拉帕利联合卡铂治疗携 BRCA1 或 BRCA2 突变的乳腺癌或卵巢癌的 I/ Ib 期研究及生物标志物分析。

J Natl Cancer Inst. 2014 May 19;106(6):dju089. doi: 10.1093/jnci/dju089. Print 2014 Jun.

7

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.奥拉帕利单药治疗携带胚系 BRCA1/2 突变的晚期癌症患者。

J Clin Oncol. 2015 Jan 20;33(3):244-50. doi: 10.1200/JCO.2014.56.2728. Epub 2014 Nov 3.

8

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.奥拉帕利治疗复发性高级别浆液性或低分化卵巢癌或三阴性乳腺癌患者的疗效：一项多中心、开放标签、非随机的 2 期临床试验。

Lancet Oncol. 2011 Sep;12(9):852-61. doi: 10.1016/S1470-2045(11)70214-5. Epub 2011 Aug 19.

9

BRCA1/2 testing: therapeutic implications for breast cancer management.BRCA1/2 检测：乳腺癌管理的治疗意义。

Br J Cancer. 2018 Jul;119(2):141-152. doi: 10.1038/s41416-018-0127-5. Epub 2018 Jun 5.

10

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.胚系BRCA1/2突变的晚期卵巢癌患者对PARP抑制剂奥拉帕尼抗肿瘤反应的基线临床预测指标。

Oncotarget. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005.

本文引用的文献

1

The Japanese Breast Cancer Society Clinical Practice Guidelines for surgical treatment of breast cancer, 2022 edition.日本乳腺癌学会乳腺癌外科治疗临床实践指南，2022 年版。

Breast Cancer. 2024 Jan;31(1):1-7. doi: 10.1007/s12282-023-01510-0. Epub 2023 Oct 16.

2

Red-flag signs and symptoms for earlier diagnosis of early-onset colorectal cancer.早期结直肠癌早期诊断的红色标志和症状。

J Natl Cancer Inst. 2023 Aug 8;115(8):909-916. doi: 10.1093/jnci/djad068.